Global CRISPR Lipid Nanoparticle Delivery Therapeutics Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

CRISPR Lipid Nanoparticle Delivery Therapeutics Market Size

• The global CRISPR Lipid Nanoparticle Delivery Therapeutics market size was valued at USD 1.28 billion in 2025 and is expected to reach USD 5.76 billion by 2033, at a CAGR of 20.70% during the forecast period
• The market growth is largely fueled by the rapid advancement of in vivo CRISPR gene editing clinical programs utilizing LNP delivery platforms, the accelerating development of mRNA and siRNA therapeutics leveraging lipid nanoparticle encapsulation, and growing recognition of LNPs as a safer, more scalable alternative to viral vectors for nucleic acid delivery
• Furthermore, rising pharmaceutical investment in LNP-CRISPR technology platforms for treating genetic disorders, oncological conditions, and cardiovascular diseases is establishing CRISPR lipid nanoparticle therapeutics as the cornerstone of next-generation precision medicine. These converging factors are accelerating the uptake of LNP-CRISPR delivery solutions, thereby significantly boosting the industry's growth

CRISPR Lipid Nanoparticle Delivery Therapeutics Market Analysis

• CRISPR lipid nanoparticle delivery therapeutics, offering a non-viral, biocompatible platform for efficient intracellular delivery of CRISPR/Cas9 components, mRNA, siRNA, and plasmid DNA, are increasingly vital components of the modern precision medicine landscape due to their lower immunogenicity, high encapsulation efficiency, and superior scalability compared to conventional viral vector-based delivery systems
• The escalating demand for CRISPR LNP therapeutics is primarily fueled by the expanding clinical pipeline of in vivo gene editing programs, the commercial success of LNP-mRNA vaccine platforms validated through global COVID-19 immunization campaigns, and growing pharmaceutical R&D investment in ionizable lipid formulations optimized for targeted CRISPR delivery to hepatic and extrahepatic tissues
• North America dominated the CRISPR lipid nanoparticle delivery therapeutics market with the largest revenue share of 41.20% in 2025, characterized by the presence of pioneering LNP-CRISPR developers including Intellia Therapeutics, CRISPR Therapeutics, Verve Therapeutics, and Alnylam Pharmaceuticals, alongside robust FDA regulatory pathways supporting accelerated clinical development of in vivo gene editing programs
• Asia-Pacific is expected to be the fastest growing region in the CRISPR lipid nanoparticle delivery therapeutics market during the forecast period due to rapidly expanding biotech ecosystems, government-backed genomic medicine initiatives, and growing clinical research activity in China, Japan, and South Korea
• The Research segment accounted for the largest market revenue share of 57.3% in 2025, driven by extensive global use of CRISPR-LNP systems in preclinical studies, gene function analysis, and therapeutic development pipelines

Report Scope and CRISPR Lipid Nanoparticle Delivery Therapeutics Market Segmentation

CRISPR Lipid Nanoparticle Delivery Therapeutics Market Trends

“AI-Optimized Ionizable Lipid Formulations Enabling Extrahepatic CRISPR Delivery”

• A significant and accelerating trend in the global CRISPR lipid nanoparticle delivery therapeutics market is the deepening integration of artificial intelligence (AI) and machine learning with LNP formulation science, enabling the rapid identification of novel ionizable lipid compositions that can deliver CRISPR gene editing components to tissues beyond the liver, including the lung, muscle, and central nervous system
• For instance, in October 2023, Mana.bio unveiled its AI-powered LNP delivery platform specifically designed to optimize lipid formulations for tissue-targeted CRISPR and RNA therapeutic delivery. This platform leverages high-throughput screening combined with predictive computational modeling to identify ionizable lipid candidates capable of achieving 40 to 60 percent editing efficiency in preclinical extrahepatic tissue models
• AI-driven LNP optimization enables features such as precise control of particle size, charge distribution, and encapsulation efficiency, which are critical parameters governing CRISPR delivery efficacy and safety. In addition, engineered ionizable lipids incorporating pH-sensitive headgroups are enabling endosomal escape optimization, which directly enhances the intracellular release of Cas9 mRNA or ribonucleoprotein complexes in target tissues with minimal off-target effects
• The seamless integration of AI-optimized LNP platforms with modular CRISPR delivery systems is facilitating centralized formulation development across multiple therapeutic indications from a single platform architecture. Through unified computational and experimental workflows, developers can adapt the same ionizable lipid scaffold to deliver diverse gene editing payloads across oncology, cardiovascular, and rare disease targets
• This trend toward more intelligent, tissue-targeted, and programmable LNP delivery systems is fundamentally reshaping the competitive landscape of CRISPR therapeutics development. Consequently, companies such as ReCode Therapeutics and Nutcracker Therapeutics are developing organ-selective LNP platforms that expand CRISPR delivery addressability beyond hepatic targets to lung, CNS, and gastrointestinal tissues
• The demand for AI-optimized CRISPR LNP therapeutics with expanded extrahepatic delivery capability is growing rapidly across both clinical and research settings, as pharmaceutical developers increasingly prioritize scalable, non-viral delivery solutions capable of enabling one-time curative gene editing across a broader range of genetic disease indications

CRISPR Lipid Nanoparticle Delivery Therapeutics Market Dynamics

Driver

“Clinical Validation of In Vivo LNP-CRISPR Programs Driving Commercial Confidence”

• The successful advancement of multiple in vivo CRISPR programs utilizing LNP delivery into late-stage clinical trials, combined with landmark clinical results demonstrating deep and durable gene editing in human patients, is a primary driver for the accelerating commercial development of the CRISPR lipid nanoparticle delivery therapeutics market
• For instance, in November 2024, results published in the New England Journal of Medicine from Intellia Therapeutics' NTLA-2001 Phase II trial confirmed an average of approximately 90% reduction in disease-related TTR protein in patients with hereditary transthyretin amyloidosis following a single IV dose of CRISPR/Cas9 delivered via LNP, establishing a landmark clinical milestone that validates the safety and efficacy of the LNP-CRISPR delivery approach in humans. Such results from key companies are expected to drive CRISPR LNP therapeutics industry growth significantly in the forecast period
• As physicians and payers increasingly recognize the potential of LNP-delivered CRISPR gene editing to provide durable, potentially curative outcomes for patients with severe genetic diseases, demand for both clinical-stage and commercially approved CRISPR LNP products is expected to grow substantially, further incentivizing R&D investment across the sector
• Furthermore, the growing portfolio of in vivo CRISPR programs delivered by proprietary LNP platforms, including CRISPR Therapeutics' CTX310 and CTX320 targeting cardiovascular disease and Verve Therapeutics' VERVE-101 for familial hypercholesterolemia, is demonstrating the versatility of LNP delivery across multiple organ systems and genetic indications beyond the initial hepatic focus
• The increasing availability of GMP-grade ionizable lipid raw materials, advancing microfluidic manufacturing technologies enabling consistent LNP batch production, and growing CDMO ecosystem specializing in LNP formulation development are reducing commercialization barriers and supporting the scale-up of LNP-CRISPR programs from clinical to commercial manufacturing stages

Restraint/Challenge

“Extrahepatic Delivery Limitations and Manufacturing Complexity”

• Systemic LNP administration has a natural tendency to accumulate predominantly in hepatocytes, creating a significant challenge for CRISPR therapeutic programs targeting tissues such as the lung, muscle, brain, and tumors where LNP biodistribution is inherently less efficient. This biological limitation restricts the addressable disease space of current LNP-CRISPR platforms and requires substantial additional formulation engineering to achieve adequate extrahepatic gene editing
• For instance, while the NTLA-2001 trial demonstrated exceptional hepatic editing efficiency, translating comparable LNP-CRISPR performance to extrahepatic targets has required the development of entirely new ionizable lipid scaffolds, organ-selective excipient combinations, and alternative delivery routes including intrathecal and intramuscular administration, all of which substantially increase development complexity and cost
• The manufacturing of LNP-based CRISPR therapeutics involves highly complex processes including high-pressure homogenization, microfluidic mixing, and precise cryopreservation, which require specialized equipment and rigorous quality control protocols to maintain batch-to-batch consistency in particle size, polydispersity index, and encapsulation efficiency. Even minor deviations in these parameters can significantly impact in vivo editing performance and patient safety profiles
• Companies such as Acuitas Therapeutics and Genevant Sciences are investing substantially in advanced LNP manufacturing platforms, proprietary ionizable lipid libraries, and analytical characterization capabilities to address these challenges and support the scalable commercial production of next-generation CRISPR LNP therapeutics
• Overcoming these challenges through continued innovation in organ-targeted LNP engineering, manufacturing process optimization, and the development of advanced analytical tools for LNP characterization will be vital for sustaining the growth momentum of the CRISPR lipid nanoparticle delivery therapeutics market across non-hepatic disease indications

CRISPR Lipid Nanoparticle Delivery Therapeutics Market Scope

The market is segmented on the basis of payload type, lipid nanoparticle type, application, therapeutic area, and end-user.

• By Payload Type

On the basis of payload type, the CRISPR Lipid Nanoparticle Delivery Therapeutics market is segmented into mRNA, CRISPR/Cas9 Components, siRNA/saRNA, Plasmid DNA, and Others. The CRISPR/Cas9 Components segment dominated the largest market revenue share of 38.6% in 2025, driven by the rapid expansion of genome editing research and therapeutic development targeting genetic disorders. These components are widely used due to their precision, efficiency, and ability to enable targeted gene knockout and correction. Increasing clinical trials focusing on CRISPR-based therapies is significantly boosting demand. Growing investment in gene-editing biotechnology companies further supports segment leadership. Strong adoption in oncology and rare disease research enhances utilization. Lipid nanoparticle (LNP) systems improve delivery efficiency and reduce degradation of CRISPR components. Expanding regulatory approvals for gene-editing studies are accelerating market growth. Rising collaborations between pharma companies and research institutes are strengthening innovation. Increasing success in preclinical studies is encouraging translational research. These factors collectively ensure dominance of CRISPR/Cas9 Components.

The mRNA segment is expected to witness the fastest growth rate of 18.9% CAGR from 2026 to 2033, driven by increasing use of mRNA-based therapeutics and vaccines delivered through lipid nanoparticle systems. Rising success of mRNA platforms in infectious disease and oncology applications is fueling expansion. Growing demand for rapid and scalable drug development technologies supports adoption. Continuous innovation in LNP-mRNA delivery systems enhances stability and efficacy. Expanding pipeline of personalized medicine therapies further drives growth. Increased funding in RNA therapeutics research strengthens market penetration. Pharmaceutical companies are investing heavily in next-generation mRNA drugs. Rising clinical trials in rare genetic and metabolic diseases support demand. Improved delivery efficiency through LNP technology enhances therapeutic outcomes. These factors position mRNA as the fastest-growing payload segment.

• By Lipid Nanoparticle Type

On the basis of lipid nanoparticle type, the market is segmented into Solid Lipid Nanoparticles, Nanostructured Lipid Carriers, Liposomes, and Others. The Liposomes segment held the largest market revenue share of 44.1% in 2025, driven by their long-standing use in drug delivery and proven ability to encapsulate nucleic acids and CRISPR payloads effectively. Liposomes offer high biocompatibility, low toxicity, and enhanced cellular uptake. Their versatility makes them widely used in gene therapy and vaccine development. Increasing application in oncology and rare disease therapeutics supports demand. Strong research focus on improving lipid-based delivery efficiency is boosting adoption. Pharmaceutical companies prefer liposomes due to established regulatory familiarity. Expanding clinical trials involving lipid-based CRISPR delivery systems further strengthen market share. Rising investment in nanomedicine is accelerating innovation. Improved stability and targeting capabilities enhance therapeutic efficiency. These factors ensure Liposomes maintain dominance in the segment.

The Nanostructured Lipid Carriers (NLCs) segment is expected to witness the fastest growth rate of 17.4% CAGR from 2026 to 2033, driven by their superior drug loading capacity and improved stability compared to traditional lipid systems. NLCs enable efficient encapsulation of complex genetic materials used in CRISPR therapies. Increasing research into next-generation nanocarriers is supporting adoption. Growing demand for targeted and sustained-release gene therapies is fueling expansion. Pharmaceutical companies are focusing on improving delivery precision for genetic editing tools. Rising use in oncology and neurological disorder treatment is further boosting demand. Enhanced scalability and manufacturing advantages support commercialization. Expanding academic research in nanotechnology-based delivery systems is accelerating innovation. Improved safety profiles are increasing clinical acceptance. These factors position NLCs as the fastest-growing lipid nanoparticle type.

• By Application

On the basis of application, the market is segmented into Therapeutics and Research. The Research segment accounted for the largest market revenue share of 57.3% in 2025, driven by extensive global use of CRISPR-LNP systems in preclinical studies, gene function analysis, and therapeutic development pipelines. Academic institutions and biotechnology firms heavily rely on these systems for genome editing research. Increasing funding for genetic engineering and precision medicine is supporting growth. Expanding collaborations between universities and pharmaceutical companies are accelerating innovation. Rising number of CRISPR-based experimental studies boosts demand. Strong focus on disease modeling and target identification further strengthens usage. Availability of advanced LNP platforms enhances research efficiency. Continuous technological advancements in gene delivery systems are driving adoption. Government and private funding initiatives are supporting genomic research globally. These factors ensure Research remains the dominant application segment.

The Therapeutics segment is expected to witness the fastest growth rate of 21.6% CAGR from 2026 to 2033, driven by the rapid transition of CRISPR-LNP technologies from research to clinical applications. Increasing approvals for gene-editing-based therapies are fueling commercialization. Rising prevalence of genetic disorders and cancers is boosting demand for targeted treatments. Pharmaceutical companies are investing heavily in CRISPR-based drug pipelines. Advancements in delivery efficiency using lipid nanoparticles are improving clinical success rates. Growing patient awareness of gene therapy options supports adoption. Expanding clinical trials across oncology, rare diseases, and infectious diseases further drive growth. Regulatory progress in gene-editing therapies is accelerating market entry. Increasing demand for personalized medicine is another key factor. These drivers position Therapeutics as the fastest-growing application segment.

• By Therapeutic Area

On the basis of therapeutic area, the CRISPR Lipid Nanoparticle Delivery Therapeutics market is segmented into Oncology, Rare Genetic Disorders, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases, and Others. The Oncology segment dominated the largest market revenue share of 41.8% in 2025, driven by the increasing application of CRISPR-based therapies for targeted cancer gene editing and tumor suppression. Rising global cancer incidence is significantly boosting demand. CRISPR-LNP systems are widely used for gene knockout and immune modulation in cancer cells. Strong investment in oncology drug development supports segment leadership. Expanding clinical trials for solid tumors and hematologic malignancies are accelerating adoption. Advances in precision oncology are improving treatment outcomes. Pharmaceutical companies are prioritizing cancer-focused gene therapies. Growing use of combination therapies enhances effectiveness. Increased funding from public and private organizations strengthens research. These factors ensure Oncology remains the dominant therapeutic area.

The Rare Genetic Disorders segment is expected to witness the fastest growth rate of 22.3% CAGR from 2026 to 2033, driven by increasing development of curative gene-editing therapies for inherited diseases. CRISPR-LNP technology offers high precision in correcting genetic mutations. Rising awareness and diagnosis of rare diseases are boosting treatment demand. Growing orphan drug incentives are encouraging pharmaceutical investment. Expanding clinical trials targeting monogenic disorders further support growth. Improved delivery systems are enhancing therapeutic safety and efficiency. Patient advocacy groups are accelerating funding and awareness. Advances in personalized medicine are driving innovation. Increasing regulatory approvals for gene therapies are strengthening market expansion. These factors position Rare Genetic Disorders as the fastest-growing therapeutic area.

• By End-User

On the basis of end-user, the market is segmented into Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, and Others. The Pharmaceutical and Biotechnology Companies segment accounted for the largest market revenue share of 62.7% in 2025, driven by extensive investment in CRISPR-based drug development and commercialization pipelines. These companies are leading innovation in lipid nanoparticle delivery platforms. Increasing focus on gene therapy commercialization supports segment dominance. Strong R&D spending in precision medicine enhances adoption. Partnerships with biotech startups are accelerating technological advancements. Growing number of clinical trials conducted by pharma companies further boosts demand. Expansion of gene-editing portfolios strengthens market leadership. Rising regulatory approvals for gene therapies support industry growth. Advanced manufacturing capabilities improve scalability of LNP-based therapeutics. These factors ensure dominance of Pharmaceutical and Biotechnology Companies.

The Academic & Research Institutes segment is expected to witness the fastest growth rate of 16.8% CAGR from 2026 to 2033, driven by increasing global funding for genomic research and gene-editing studies. Universities and research centers are major contributors to early-stage CRISPR innovation. Rising collaboration with pharmaceutical companies is boosting technology transfer. Growing availability of research grants supports adoption of LNP-based delivery systems. Expansion of biotechnology education programs further fuels demand. Increasing focus on translational research accelerates clinical applications. Advanced laboratory infrastructure enhances experimental capabilities. Rising interest in personalized medicine research strengthens usage. Government initiatives promoting genomics research also contribute to growth. These factors make Academic & Research Institutes the fastest-growing end-user segment.

CRISPR Lipid Nanoparticle Delivery Therapeutics Market Regional Analysis

• North America dominated the CRISPR lipid nanoparticle delivery therapeutics market with the largest revenue share of 41.20% in 2025, driven by the presence of the world's leading LNP-CRISPR companies, a well-developed CDMO ecosystem specializing in LNP manufacturing, robust government funding through BARDA and NIH for LNP technology development, and the highest concentration of active in vivo CRISPR clinical trials globally
• Consumers and healthcare providers in the region benefit from advanced FDA regulatory pathways supporting accelerated LNP-CRISPR development, including RMAT designation, breakthrough therapy status, and fast-track designation for CRISPR therapeutics targeting rare and life-threatening genetic diseases
• This widespread adoption is further supported by high levels of public and private biopharmaceutical R&D investment, a sophisticated clinical infrastructure supporting LNP-CRISPR trial conduct, and increasing collaboration between LNP technology developers and major pharmaceutical companies, establishing North America as the dominant and most commercially advanced LNP-CRISPR market globally

U.S. CRISPR Lipid Nanoparticle Delivery Therapeutics Market Insight

The U.S. CRISPR lipid nanoparticle delivery therapeutics market captured the largest revenue share within North America in 2025, fueled by the rapid commercial expansion of LNP-CRISPR programs from pioneering companies including Intellia Therapeutics, CRISPR Therapeutics, Verve Therapeutics, and Beam Therapeutics. The U.S. market is projected to reach an estimated USD 1.84 billion by 2032, driven by favorable FDA regulatory engagement, growing payer recognition of the transformative value of one-time curative LNP-CRISPR treatments, and expanding manufacturing infrastructure. Moreover, the 2025 groundbreaking single-patient trial at the Children's Hospital of Philadelphia and University of Pennsylvania using Acuitas LNPs to deliver the world's first personalized CRISPR therapy is significantly contributing to the market's expansion.

Europe CRISPR Lipid Nanoparticle Delivery Therapeutics Market Insight

The Europe CRISPR lipid nanoparticle delivery therapeutics market is projected to expand at a substantial CAGR throughout the forecast period, primarily driven by strong EMA regulatory support for advanced therapy medicinal products incorporating LNP delivery, growing investment in LNP manufacturing infrastructure across Germany, France, and the U.K., and the expanding European clinical trial landscape for LNP-CRISPR gene editing programs. European companies including BioNTech SE in Germany and Acuitas Therapeutics are playing central roles in advancing ionizable lipid LNP technology that underpins the clinical CRISPR delivery pipeline globally. In addition, the EU Horizon program's ongoing investment in LNP-based gene therapy research is supporting the expansion of European academic and commercial LNP-CRISPR development capabilities.

U.K. CRISPR Lipid Nanoparticle Delivery Therapeutics Market Insight

The U.K. CRISPR lipid nanoparticle delivery therapeutics market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by the MHRA's progressive regulatory framework for LNP-based advanced therapeutics, robust NHS investment in genomic medicine, and the presence of leading academic centers including the Wellcome Sanger Institute and the Francis Crick Institute conducting pioneering LNP-CRISPR delivery research. The U.K.'s Genomics England program and growing precision medicine investment are creating a supportive ecosystem for clinical translation of LNP-CRISPR programs.

Germany CRISPR Lipid Nanoparticle Delivery Therapeutics Market Insight

The Germany CRISPR lipid nanoparticle delivery therapeutics market is expected to expand at a considerable CAGR during the forecast period, fueled by the presence of BioNTech SE, which leverages its globally validated mRNA-LNP manufacturing infrastructure for advancing therapeutic LNP-CRISPR programs, alongside strong government investment in biotechnology innovation and a well-developed pharmaceutical manufacturing ecosystem. Germany's emphasis on precision medicine and strong academic-industry collaboration in genomic research promotes the development of advanced LNP-CRISPR formulations, particularly in oncology and rare disease applications.

Asia-Pacific CRISPR Lipid Nanoparticle Delivery Therapeutics Market Insight

The Asia-Pacific CRISPR lipid nanoparticle delivery therapeutics market is poised to grow at the fastest CAGR of 24.0% during the forecast period of 2026 to 2033, driven by rapidly expanding biopharmaceutical R&D investments, growing government support for genomic medicine and nanotechnology innovation, and increasing clinical trial activity in China, Japan, South Korea, and India. For instance, in March 2025, researchers at East China Normal University and YolTech Therapeutics in Shanghai developed LNPs to deliver CRISPR-Cas9 for the treatment of primary hyperoxaluria type 1, demonstrating the region's growing capability in LNP-CRISPR therapeutic development. In addition, initiatives such as China's 'Made in China 2025' plan and India's BIRAC are promoting LNP nanotechnology R&D, further accelerating regional market growth.

Japan CRISPR Lipid Nanoparticle Delivery Therapeutics Market Insight

The Japan CRISPR lipid nanoparticle delivery therapeutics market is gaining momentum due to the country's strong tradition of academic research in LNP drug delivery science, increasing industry investment in RNA therapeutics, and growing regulatory support for advanced gene therapy and nucleic acid medicine development. Japan's national precision medicine initiative and increasing clinical collaboration between Japanese universities and global LNP-CRISPR developers are accelerating the translation of LNP delivery innovation into clinical applications.

China CRISPR Lipid Nanoparticle Delivery Therapeutics Market Insight

The China CRISPR lipid nanoparticle delivery therapeutics market accounted for the largest market revenue share in Asia-Pacific in 2025, attributed to the country's largest number of CRISPR clinical trials globally, rapidly expanding domestic biotech sector, and strong government support for gene therapy and nanomedicine innovation. Domestic companies including YolTech Therapeutics and academic research groups at leading Chinese universities are developing proprietary LNP formulations for CRISPR delivery, while international partnerships are facilitating technology transfer and clinical advancement of LNP-CRISPR programs in the Chinese healthcare market.

CRISPR Lipid Nanoparticle Delivery Therapeutics Market Share

The CRISPR Lipid Nanoparticle Delivery Therapeutics industry is primarily led by well-established companies, including:

• Intellia Therapeutics (U.S.)
• CRISPR Therapeutics AG (Switzerland)
• Verve Therapeutics (U.S.)
• Alnylam Pharmaceuticals (U.S.)
• Moderna Inc. (U.S.)
• BioNTech SE (Germany)
• Precision BioSciences (U.S.)
• Acuitas Therapeutics (Canada)
• Genevant Sciences (U.S.)
• Arcturus Therapeutics (U.S.)
• Merck KGaA (Germany)
• Pfizer Inc. (U.S.)
• AstraZeneca (U.K.)
• Beam Therapeutics (U.S.)
• Prime Medicine (U.S.)
• Tessera Therapeutics (U.S.)
• Tome Biosciences (U.S.)
• Mana.bio (U.S.)
• ReCode Therapeutics (U.S.)
• Nutcracker Therapeutics (U.S.)

Latest Developments in Global CRISPR Lipid Nanoparticle Delivery Therapeutics Market

• In January 2024, Tome Biosciences and Genevant Sciences entered into a strategic collaboration valued at approximately USD 114.3 million, combining Tome's programmable genomic integration expertise with Genevant's proprietary LNP technology to develop in vivo gene editing solutions for rare liver conditions. This landmark partnership underscored the strategic importance of LNP delivery technology licensing in advancing next-generation in vivo CRISPR therapeutic programs.
• In October 2023, Mana.bio unveiled its AI-powered lipid nanoparticle delivery platform, designed to accelerate the identification of novel ionizable lipid formulations for organ-selective CRISPR and RNA therapeutic delivery. The AI-driven platform integrates high-throughput experimental screening with machine learning-based prediction to optimize LNP compositions for extrahepatic tissue targeting, expanding the addressable disease space for LNP-CRISPR therapeutics.
• In November 2024, results published in the New England Journal of Medicine from Intellia Therapeutics' NTLA-2001 Phase II trial demonstrated approximately 90% reduction in TTR protein levels in patients with hereditary transthyretin amyloidosis following a single IV dose of LNP-delivered CRISPR/Cas9, confirming deep and durable in vivo gene editing in humans. A companion program NTLA-2002 further demonstrated a 95% reduction in hereditary angioedema episode frequency, collectively validating LNP-CRISPR as a transformative clinical platform
• In March 2025, researchers at East China Normal University and YolTech Therapeutics in Shanghai published preclinical data demonstrating that a single administration of an LNP-CRISPR-Cas9 system achieved sustained therapeutic effects in a mouse model of primary hyperoxaluria type 1, advancing the clinical development case for non-viral LNP delivery of CRISPR therapeutics for rare metabolic liver diseases beyond Western markets
• In June 2025, Eli Lilly completed the acquisition of Verve Therapeutics, integrating its proprietary LNP-base editing platform targeting cardiovascular gene editing into Lilly's precision medicine portfolio. This acquisition, representing a major pharmaceutical company's direct investment in LNP-CRISPR delivery technology, signaled strong commercial validation of the therapeutic potential of next-generation LNP-delivered gene editing for cardiovascular disease

SKU-75803